WITHDRAWN: Acute Cellular Rejection and Infection Rates in Alemtuzumab vs Traditional Induction Therapy Agents for Lung and Heart Transplantation: A Systematic …
KHC Li, JCS Ho, B Recaldin, M Gong, J Ho, G Li… - Transplantation …, 2018 - Elsevier
The Publisher regrets that this article is an accidental duplication of an article that has
already been published in Transplant Proc. 2018; 50 (10): 3739-3747, https://doi …
already been published in Transplant Proc. 2018; 50 (10): 3739-3747, https://doi …
Acute Cellular Rejection and Infection Rates in Alemtuzumab vs Traditional Induction Therapy Agents for Lung and Heart Transplantation: A Systematic Review and …
KHC Li, JCS Ho, B Recaldin, M Gong, J Ho, G Li… - Transplantation …, 2018 - Elsevier
Abstract Background and Objectives Heart and lung transplantation is a high-risk procedure
requiring intensive immunosuppressive therapy for preventing organ rejection …
requiring intensive immunosuppressive therapy for preventing organ rejection …
Acute Cellular Rejection and Infection Rates in Alemtuzumab vs Traditional Induction Therapy Agents for Lung and Heart Transplantation: A Systematic Review and …
KHC Li, JCS Ho, B Recaldin… - Transplantation …, 2018 - pubmed.ncbi.nlm.nih.gov
Background and objectives Heart and lung transplantation is a high-risk procedure requiring
intensive immunosuppressive therapy for preventing organ rejection. Alemtuzumab, a CD52 …
intensive immunosuppressive therapy for preventing organ rejection. Alemtuzumab, a CD52 …
WITHDRAWN: Acute Cellular Rejection and Infection Rates in Alemtuzumab vs Traditional Induction Therapy Agents for Lung and Heart Transplantation: A Systematic …
KHC Li, JCS Ho, B Recaldin, M Gong, J Ho… - Transplantation …, 2018 - europepmc.org
The Publisher regrets that this article is an accidental duplication of an article that has
already been published in Transplant Proc. 2018; 50 (10): 3739-3747, https://doi …
already been published in Transplant Proc. 2018; 50 (10): 3739-3747, https://doi …
Acute Cellular Rejection and Infection Rates in Alemtuzumab vs Traditional Induction Therapy Agents for Lung and Heart Transplantation: A Systematic Review and …
KHC Li, JCS Ho, B Recaldin, M Gong, J Ho… - Transplantation …, 2018 - europepmc.org
Methods PubMed and EMBASE were searched to October 1, 2017, for articles on
alemtuzumab in cardiothoracic transplant surgery. Of the 433 studies retrieved, 8 were …
alemtuzumab in cardiothoracic transplant surgery. Of the 433 studies retrieved, 8 were …
WITHDRAWN: Acute Cellular Rejection and Infection Rates in Alemtuzumab vs Traditional Induction Therapy Agents for Lung and Heart Transplantation: A Systematic …
KHC Li, JCS Ho, B Recaldin… - Transplantation …, 2018 - pubmed.ncbi.nlm.nih.gov
The Publisher regrets that this article is an accidental duplication of an article that has
already been published in Transplant Proc. 2018; 50 (10): 3739-3747, https://doi …
already been published in Transplant Proc. 2018; 50 (10): 3739-3747, https://doi …